XRpro Technology for the Detection and Evaluation of Carcinogens

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$200,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA150404-01
Agency Tracking Number:
CA150404
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D, LOS ALAMOS, NM, 87544
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
147452275
Principal Investigator:
BENJAMIN WARNER
(505) 412-2345
WARNER@CALDERA-PHARMACEUTICALS.COM
Business Contact:
() -
court@cpsci.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinogenic and biotransformation pathways. This project addresses challenges listed in PA-09-187, including the measure ment of carcinogens directly, without antibodies, dyes, tags, or radioactive materials. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government